Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DHC PLUS vs NALBUPHINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
DHC PLUS is a combination of codeine (an opioid agonist) and homatropine (an anticholinergic). Codeine binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering perception of pain. Homatropine antagonizes muscarinic acetylcholine receptors, reducing GI motility and secretions, which may decrease opioid-induced nausea and vomiting.
Mixed opioid agonist-antagonist; agonist at κ-opioid receptors and antagonist/partial agonist at μ-opioid receptors.
Relief of acute moderate pain in adults,Off-label: management of diarrhea
Moderate to severe pain,Supplement to balanced anesthesia,Preoperative and postoperative analgesia,Obstetrical analgesia during labor and delivery
1-2 tablets (dihydrocodeine 40 mg/paracetamol 500 mg per tablet) orally every 4-6 hours as needed, maximum 8 tablets per day.
10-20 mg IV/IM/SC every 3-6 hours as needed for pain; maximum single dose 20 mg, maximum total daily dose 160 mg.
3.5-5 hours for dihydrocodeine; prolonged in hepatic impairment (up to 8-10 hours) and may require dose adjustment.
Terminal elimination half-life is 5 hours; clinically, in hepatic impairment or elderly, half-life may be prolonged up to 8-10 hours.
Codeine is metabolized by CYP2D6 to morphine (active), and by CYP3A4 to norcodeine. Homatropine is metabolized via ester hydrolysis and N-demethylation. Both are excreted renally.
Hepatic metabolism primarily via glucuronidation and oxidative pathways; minor involvement of CYP450 enzymes.
Renal: ~90% as glucuronide conjugates, with 10% as unchanged dihydrocodeine and 5-10% as nordihydrocodeine; biliary/fecal: <5%.
Primarily hepatic metabolism; <5% excreted unchanged in urine; about 70% excreted in feces via biliary elimination.
20-30% bound to albumin.
Approximately 50% bound to plasma proteins, primarily albumin.
1.5 L/kg; reflects moderate tissue distribution due to lipophilicity.
2.3 L/kg; indicates extensive tissue distribution, consistent with moderate lipophilicity.
Oral: ~60-70% due to first-pass metabolism; subcutaneous: ~80-90%; rectal: ~70-80%.
Intravenous: 100%; Intramuscular: approximately 80%; Oral: negligible (<20%) due to extensive first-pass metabolism.
GFR 30-50 m L/min: Administer every 6-8 hours; GFR 10-29 m L/min: Administer every 8-12 hours; GFR <10 m L/min: Avoid or use with extreme caution, reduce dose by 50% and monitor for toxicity.
Cr Cl 30-50 m L/min: administer 75% of normal dose every 6 hours; Cr Cl <30 m L/min: administer 50% of normal dose every 8 hours.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Reduce dose by 50% and extend interval to every 8 hours; Child-Pugh Class C: Avoid use due to risk of paracetamol hepatotoxicity and dihydrocodeine accumulation.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50% or use alternative.
Not recommended for children under 12 years of age. For adolescents (12-18 years): Same adult dosing based on weight, typically 1 tablet every 4-6 hours, maximum 4 tablets per day.
0.1-0.2 mg/kg IV/IM/SC every 3-6 hours as needed; maximum single dose 20 mg.
Initiate with lowest effective dose, 1 tablet every 6-8 hours; maximum 4 tablets per day; monitor for CNS depression and constipation.
Initiate at 50% of adult dose (5-10 mg) and titrate cautiously due to increased sensitivity and risk of respiratory depression.
Warning: Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; interactions with alcohol and CNS depressants; risk of medication errors with codeine; risks from concomitant use with benzodiazepines or other CNS depressants; and risks of use in children under 12 years, and in adolescents with certain respiratory conditions.
Risk of respiratory depression, particularly in opioid-naive patients; risk of dependence and abuse; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Risk of respiratory depression,CYP2D6 ultrarapid metabolizers: increased toxicity,Anticholinergic effects (e.g., urinary retention, constipation),Use caution in elderly, renal/hepatic impairment,Avoid in patients with severe respiratory conditions
Respiratory depression may occur, especially in elderly, cachectic, or debilitated patients,Avoid use in patients with head injury or increased intracranial pressure,May precipitate withdrawal in opioid-dependent patients,Hypotension, biliary tract spasm, and seizure risk
Hypersensitivity to codeine, homatropine, or any component,Significant respiratory depression,Acute or severe bronchial asthma,Paralytic ileus,Children under 12 years (codeine)
Hypersensitivity to nalbuphine or any component,Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting,Suspected or known gastrointestinal obstruction
Avoid alcohol as it increases sedation and hepatotoxicity risk. High-fat meals may delay absorption but not significantly alter efficacy.
No significant food-drug interactions. Avoid alcohol and grapefruit juice as they may enhance CNS depression.
DHC PLUS (dihydrocodeine/paracetamol): First trimester risk of neural tube defects with paracetamol use is low but not zero; dihydrocodeine may cause respiratory depression in neonate if used near term. Chronic use in third trimester can lead to neonatal opioid withdrawal syndrome.
FDA Category C. First trimester: Limited human data, no evidence of major malformations in animal studies at 4-6x MRHD. Second/third trimester: Chronic use may cause neonatal opioid withdrawal syndrome (NOWS) including irritability, hypertonia, tremors, poor feeding. Use only if benefit outweighs risk.
Dihydrocodeine and paracetamol are excreted in breast milk in low amounts. M/P ratio for dihydrocodeine is approximately 0.5-1.0. Use with caution; monitor infant for sedation and respiratory depression. Paracetamol is considered compatible with breastfeeding.
Excreted in human milk in low concentrations (M/P ratio ~0.6). Relative infant dose estimated 0.5-1% of maternal weight-adjusted dose. Monitor infant for sedation and poor feeding. American Academy of Pediatrics considers compatible with breastfeeding with caution.
Increased clearance of dihydrocodeine in pregnancy may require dose adjustment; however, avoid use if possible. Paracetamol pharmacokinetics are minimally altered; standard dosing is acceptable. Short-term use only; avoid high doses of paracetamol (>2g/day) in third trimester.
No specific dose adjustments recommended for pregnancy. Increased clearance and volume of distribution in third trimester may potentially reduce efficacy; titrate to effect. Avoid in prolonged labor due to risk of fetal bradycardia.
DHC PLUS contains dihydrocodeine and paracetamol. Avoid in CYP2D6 ultra-rapid metabolizers due to morphine toxicity risk. Use with caution in patients with respiratory compromise, as dihydrocodeine can cause respiratory depression. Monitor liver function with prolonged paracetamol use.
Nalbuphine is a mixed agonist-antagonist opioid with a ceiling effect for respiratory depression, making it safer than pure agonists. It can precipitate withdrawal in opioid-dependent patients. Monitor for sedation and hypotension. Reversal with naloxone may be less effective. Use with caution in hepatic impairment. Not recommended for chronic pain due to psychotomimetic effects.
Do not exceed recommended dose due to paracetamol hepatotoxicity risk.,Avoid alcohol while taking this medication.,May cause drowsiness or dizziness; avoid driving or operating machinery.,Take with food if gastrointestinal upset occurs.,Do not crush or chew extended-release formulations.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, sleep aids) as they can increase dizziness and drowsiness.,Do not drive or operate heavy machinery until you know how nalbuphine affects you.,Report any signs of withdrawal (e.g., restlessness, tearing, runny nose, yawning, sweating) if you have been taking other opioids.,Seek emergency care if you experience trouble breathing, severe dizziness, or hallucinations.,Do not stop abruptly; tapering may be needed to avoid withdrawal symptoms.
No interactions on record
"The combination of trifluoperazine, a phenothiazine antipsychotic, with nalbuphine, a mixed opioid agonist-antagonist, can lead to additive central nervous system (CNS) depression, including increased sedation, respiratory depression, and hypotension. Trifluoperazine may enhance the depressant effects of nalbuphine on the brainstem respiratory centers and vasomotor centers. Clinically, this interaction may result in excessive sedation, respiratory compromise, and orthostatic hypotension, particularly in elderly or debilitated patients."
"Combined use of nalbuphine, a mixed opioid agonist-antagonist, with entacapone, a catechol-O-methyltransferase (COMT) inhibitor, may increase the risk of opioid-related adverse effects, including respiratory depression and sedation, due to additive central nervous system depression. Entacapone can also inhibit the metabolism of catecholamines, potentially exacerbating opioid-induced constipation and urinary retention. Clinically, patients may experience enhanced sedation or respiratory compromise, particularly in elderly or debilitated populations."
"Concomitant use of clozapine and nalbuphine may potentiate central nervous system (CNS) depression, leading to additive sedative and respiratory depressant effects. Both drugs act on the CNS via distinct mechanisms but converge on common pathways, increasing the risk of hypotension, bradycardia, and profound sedation. Clinically, patients may experience excessive drowsiness, confusion, or respiratory compromise, particularly in those with pre-existing comorbidities or concurrent use of other CNS depressants."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DHC PLUS vs NALBUPHINE, answered by our medical review team.
DHC PLUS is a Antihistamine-Decongestant that works by DHC PLUS is a combination of codeine (an opioid agonist) and homatropine (an anticholinergic). Codeine binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering perception of pain. Homatropine antagonizes muscarinic acetylcholine receptors, reducing GI motility and secretions, which may decrease opioid-induced nausea and vomiting.. NALBUPHINE is a Opioid Agonist-Antagonist that works by Mixed opioid agonist-antagonist; agonist at κ-opioid receptors and antagonist/partial agonist at μ-opioid receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DHC PLUS and NALBUPHINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DHC PLUS is: 1-2 tablets (dihydrocodeine 40 mg/paracetamol 500 mg per tablet) orally every 4-6 hours as needed, maximum 8 tablets per day.. The standard adult dose of NALBUPHINE is: 10-20 mg IV/IM/SC every 3-6 hours as needed for pain; maximum single dose 20 mg, maximum total daily dose 160 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DHC PLUS and NALBUPHINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DHC PLUS is classified as Category C. DHC PLUS (dihydrocodeine/paracetamol): First trimester risk of neural tube defects with paracetamol use is low but not zero; dihydrocodeine may cause respiratory depression in neon. NALBUPHINE is classified as Category A/B. FDA Category C. First trimester: Limited human data, no evidence of major malformations in animal studies at 4-6x MRHD. Second/third trimester: Chronic use may cause neonatal opioi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.